INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving aTyr Pharma, Inc. following the failure of its Phase 3 clinical trial results, which significantly impacted the company's stock price [1][3]. Group 1: Company Overview - aTyr Pharma, Inc. is a publicly traded company on NASDAQ under the ticker ATYR [1]. - The company recently announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod, which involved 268 patients with pulmonary sarcoidosis [3]. Group 2: Clinical Trial Results - The Phase 3 EFZO-FIT™ study did not meet its primary endpoint, leading to a significant decline in aTyr's stock price [3]. - Following the announcement of the trial results, aTyr's stock price dropped by $5.02 per share, representing an 83.25% decrease, closing at $1.01 per share on September 15, 2025 [3]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding possible securities fraud or other unlawful practices by aTyr and its officers or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].